enoxaparine becat 10000 iu (100 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.
laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 10000 - solution for injection in pre-filled syringe - 10000 iu (100 mg)/1 ml - enoxaparin sodium 10000 iu/ml - enoxaparin
enoxaparine becat 12000 iu (120 mg)/0,8 ml inj. sol. i.v./s.c. pre-filled syr.
laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 12000 iu (120 mg)/0,8 ml - enoxaparin sodium 15000 iu/ml - enoxaparin
enoxaparine becat 15000 iu (150 mg)/1 ml inj. sol. i.v./s.c. pre-filled syr.
laboratorios farmaceuticos rovi s.a. - enoxaparin sodium 15000 - solution for injection in pre-filled syringe - 15000 iu (150 mg)/1 ml - enoxaparin sodium 15000 iu/ml - enoxaparin
enoxaparin sandoz 2000 iu (20 mg) 0.2 ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -
enoxaparin sandoz 4000 iu (40 mg) 0.4 ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -
enoxaparin sandoz 6000 iu (60 mg) 0.6 ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -
enoxaparin inhixa
k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg/ml - enoxaparin - enoxaparin inhixa is indicated in adults for:• prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
enoxaparin inhixa forte
k.s.kim international (sk- pharma) ltd., israel - enoxaparin sodium - solution for injection - enoxaparin sodium 150 mg/ml - enoxaparin - enoxaparin inhixa forte is indicated in adults for: • prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
enoxaparin ledraxen
pharmalogic ltd - enoxaparin sodium - solution for injection - enoxaparin sodium 100 mg / 1 ml - enoxaparin - enoxaparin is indicated in adults for:• prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery. • prophylaxis of venous thromboembolic disease in medical patients with an acute illness (such as acute heart failure, respiratory insufficiency, severe infections or rheumatic diseases) and reduced mobility at increased risk of venous thromboembolism. • treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), excluding pe likely to require thrombolytic therapy or surgery. • prevention of thrombus formation in extra corporeal circulation during haemodialysis. • acute coronary syndrome: - treatment of unstable angina and non st-segment elevation myocardial infarction (nstemi), in combination with oral acetylsalicylic acid. - treatment of acute st-segment elevation myocardial infarction (stemi) including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
enoxaparin winthrop forte enoxaparin sodium 150 mg/1 ml injection syringe with automatic safety lock system
sanofi-aventis australia pty ltd - enoxaparin sodium -